NDRA - ENDRA Life Sciences Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8600
+0.0300 (+1.64%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.8600
Open1.9000
Bid1.87 x 800
Ask1.99 x 800
Day's Range1.8500 - 1.9198
52 Week Range1.4400 - 5.7500
Volume43,127
Avg. Volume447,259
Market Cap13.806M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE20 days ago

    ENDRA Life Sciences Issues Shareholder Letter

    ANN ARBOR, MI / ACCESSWIRE / January 2, 2019 / ENDRA Life Sciences Inc. ("ENDRA") (NDRA), a developer of enhanced ultrasound technologies, has released a letter to its shareholders from Francois Michelon, Chairman and CEO. On the operational front, we advanced development of our Thermo Acoustic Enhanced Ultrasound (TAEUS) clinical technology targeting Non-Alcoholic Fatty Liver Disease (NAFLD), setting the stage for a European launch in 2019. ENDRA's overarching goals are to broaden access to better healthcare and to drive shareholder value.

  • ACCESSWIRElast month

    ENDRA Life Sciences Provides Update on First Human Study

    ANN ARBOR, MI / ACCESSWIRE / December 17, 2018 / ENDRA Life Sciences Inc. (''ENDRA'') (NDRA), a developer of enhanced ultrasound technologies, announced today that the Robarts Research Institute has completed its initial healthy subject enrollment and data collection of 25 subjects. The Robarts Research Institute team requested and received authorization to expand the study to 50 subjects, which would double the tissue data sets from ENDRA's Thermo-Acoustic Enhanced Ultrasound (TAEUS™) and gain additional workflow and usability information, expanding the pool of study subjects to be representative of the population distribution of liver fat.

  • ACCESSWIRE2 months ago

    ENDRA Life Sciences to Present at the 11th Annual LD Micro Main Event on December 5, 2018

    Management to Live Webcast Company Presentation ANN ARBOR, MI / ACCESSWIRE / December 3, 2018 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has ...

  • ACCESSWIRE2 months ago

    ENDRA Life Sciences to Present at Upcoming Investor Conferences

    The Benchmark Company Discovery One-on-One Conference on November 29 & the 11th Annual LD Micro Main Event Conference on December 5 ANN ARBOR, MI / ACCESSWIRE / November 26, 2018 / ENDRA Life Sciences ...

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Targa Resources, IntriCon, ENDRA Life Sciences, Coffee Holding Co., Orion Group, and Carbon Black — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE2 months ago

    ENDRA Life Sciences Announces Closing of Public Offering and Exercise of Over-Allotment Option

    ANN ARBOR, MI / ACCESSWIRE / November 13, 2018 / ENDRA Life Sciences Inc. ("ENDRA" or the "Company") (NDRA), a developer of enhanced ultrasound technologies, has closed its previously announced underwritten public offering of 1,205,000 shares of common stock at an offering price of $3.90 per share. In connection with the offering, the underwriter exercised in full its over-allotment option to purchase an additional 180,750 shares of common stock at the public offering price to cover over-allotments. All of the common shares were offered by the Company.

  • ACCESSWIRE2 months ago

    ENDRA Life Sciences Prices Public Offering of Common Stock

    ("ENDRA" or the "Company") (NDRA), a developer of enhanced ultrasound technologies, has priced its previously announced underwritten public offering of 1,205,000 shares of common stock at an offering price of $3.90 per share. In addition, the ENDRA has granted the underwriter a 45-day option to purchase up to an additional 180,750 shares to cover over-allotments, if any. All of the shares are being offered by the Company.

  • ACCESSWIRE2 months ago

    ENDRA Life Sciences Announces Proposed Public Offering of Common Stock

    ANN ARBOR, MI / ACCESSWIRE / November 7, 2018 / ENDRA Life Sciences Inc. (''ENDRA'' or the ''Company'') (NDRA), a developer of enhanced ultrasound technologies, is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. ENDRA expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the common shares are being offered by the Company.

  • ACCESSWIRE3 months ago

    ENDRA Life Sciences Reports Third Quarter 2018 Financial Results

    Management to Host Conference Call Today at 4:30 p.m. ET ANN ARBOR, MI / ACCESSWIRE / November 5, 2018 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, ...

  • TheStreet.com3 months ago

    My Stock of the Week: ENDRA Life Sciences

    Some of the doom and gloom has lifted this morning as market players are focusing more on positive news. Given the huge size of the market and the need for a cheaper diagnostic tool, we believe NDRA has more upside.

  • ACCESSWIRE3 months ago

    ENDRA Life Sciences to Showcase TAEUS(TM) Liver Application at Three Global Liver and Imaging Conferences in November 2018

    ENDRA to Participate in The Liver Meeting ® 2018 from November 9-13, the Interdisciplinary Ultrasound Congress 2018 from November 14-16 and the RSNA ® 2018 Annual Meeting from November 25-30 ANN ARBOR, ...

  • ACCESSWIRE3 months ago

    ENDRA Life Sciences to Host Third Quarter 2018 Results Conference Call on Monday, November 5, 2018 at 4:30 p.m. ET

    ANN ARBOR, MI / ACCESSWIRE / October 23, 2018 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, will hold a conference call on Monday, November ...

  • ACCESSWIRE3 months ago

    ENDRA Life Sciences Receives Approval to Initiate Human Studies of its TAEUS(TM) Device Targeting Non-Alcoholic Fatty Liver Disease

    ANN ARBOR, MI / ACCESSWIRE / October 16, 2018 / ENDRA Life Sciences Inc. ("ENDRA") (NDRA), a developer of enhanced ultrasound technologies, through its collaborators at Robarts Research, has received approval from Health Canada for an Investigational Testing Authorization (ITA) to commence human studies with ENDRA's Thermo-Acoustic Enhanced Ultrasound (TAEUS™) clinical system targeting Non-Alcoholic Fatty Liver Disease (NAFLD). The ITA application was reviewed under a class II designation and the study will be conducted in collaboration with Imaging Laboratories at Robarts Research in London, Canada.

  • ACCESSWIRE3 months ago

    ENDRA Life Sciences Announces Closing of Public Offering and Exercise of Over-Allotment Option

    ANN ARBOR, MI / ACCESSWIRE / October 15, 2018 / ENDRA Life Sciences Inc. ("ENDRA" or the "Company") (NDRA), a developer of enhanced ultrasound technologies, has closed its previously announced underwritten public offering of 1,285,000 shares of common stock at an offering price to the public of $2.10 per share. In connection with the offering, the underwriter exercised in full its over-allotment option to purchase an additional 192,750 shares of common stock at the public offering price to cover over-allotments.

  • ACCESSWIRE3 months ago

    ENDRA Life Sciences Inc. Prices Public Offering of Common Stock

    ANN ARBOR, MI / ACCESSWIRE / October 11, 2018 / ENDRA Life Sciences Inc. ("ENDRA" or the "Company") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, today announced ...

  • Benzinga3 months ago

    The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 10) Merck & Co., Inc. (NYSE: MRK ) Kezar Life Sciences ...

  • ACCESSWIRE3 months ago

    ENDRA Life Sciences Inc. Announces Proposed Public Offering of Common Stock

    ANN ARBOR, MI / ACCESSWIRE / October 10, 2018 / ENDRA Life Sciences Inc. (''ENDRA'' or the ''Company'') (NASDAQ: NDRA), a leading developer of photo- and thermo-acoustic technology to bring new capabilities ...

  • ACCESSWIRE5 months ago

    ENDRA Life Sciences to Showcase TAEUS(TM) Liver Application at the EASL Non-Alcoholic Fatty Liver Disease Summit in Geneva Switzerland on September 20-22, 2018

    ANN ARBOR, MI / ACCESSWIRE / August 29, 2018 / ENDRA Life Sciences Inc. ("ENDRA") (NDRA), a developer of enhanced ultrasound technologies will attend the EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit in Geneva, Switzerland on September 20-22, 2018. The summit will be hosted by the European Association for the Study of the Liver (EASL) and ENDRA will highlight the current status of their research and development on the TAEUS™ fatty liver application.

  • ACCESSWIRE5 months ago

    ENDRA Life Sciences Reports Second Quarter 2018 Financial Results

    Management to Host Conference Call Today at 4:30 p.m. EDT ANN ARBOR, MI / ACCESSWIRE / August 13, 2018 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, ...

  • ACCESSWIRE6 months ago

    ENDRA Life Sciences Granted Two U.S. Patents For Correcting Fat-Induced Aberrations & Imaging Biological Tissue Structures

    ANN ARBOR, MI / ACCESSWIRE / July 31, 2018 / ENDRA Life Sciences Inc. ("ENDRA") (NDRA), a developer of enhanced ultrasound technologies, has been awarded U.S. Patent Number 10,022,107 from the U.S. Patent and Trademark Office (USPTO) for "Method And System For Correcting Fat-Induced Aberrations" and U.S. Patent Number 10,028,662 from the U.S. Patent and Trademark Office (USPTO) for "Systems And Methods For Imaging Biological Tissue Structures". ENDRA expects to utilize both inventions with its Thermo-Acoustic Enhanced Ultrasound (TAEUS™) clinical products. The newly issued '107 patent covers a method and system for correcting fat-induced aberrations in conventional ultrasound imaging by utilizing thermoacoustic data of the scan region to estimate a fat map that can then be utilized by ultrasound reconstruction to correct for errors in speed of sound.

  • ACCESSWIRE6 months ago

    ENDRA Life Sciences to Host Second Quarter 2018 Results Conference Call on Monday, August 13, 2018 at 4:30 p.m. ET

    ANN ARBOR, MI / ACCESSWIRE / July 25, 2018 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, will hold a conference call on Monday, August ...

  • ACCESSWIRE6 months ago

    ENDRA Life Sciences Granted U.S. Patent for Magnetic Resonance Imaging (MRI) Safety Based on TAEUS Technology

    Tissue heating is a significant safety concern for modern high field MRI systems. ENDRA's '147 patent defines a novel and unique way to estimate localized tissue energy absorption, prior to an MRI scan.

  • ACCESSWIRE7 months ago

    ENDRA Life Sciences Completes Private Placement of $1.1 Million of Convertible Secured Notes and Warrants

    ENDRA Executive Management Participates to Strengthen the Company's Financial Position Ahead of Key Milestones ANN ARBOR, MI / ACCESSWIRE / July 2, 2018 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ: ...

  • ACCESSWIRE8 months ago

    ENDRA Life Sciences Granted Third U.S. Patent for Non-Invasive Fat Assessment to Support TAEU(TM) Clinical Product Targeting Non-Alcoholic Fatty Liver Disease

    ANN ARBOR, MI / ACCESSWIRE / June 5, 2018 / ENDRA Life Sciences Inc. ("ENDRA") (NDRA), a developer of enhanced ultrasound technologies, has been awarded U.S. Patent Number 9,980,677 from the U.S. Patent and Trademark Office ("USPTO") for a non-invasive fat assessment system in its Thermo-Acoustic Enhanced Ultrasound (TAEUS™) clinical products, the first of which is expected to be deployed in the second half of 2018. This third patent complements the company's recently granted U.S. Patent Number 9,888,880 from the USPTO for non-invasive fat assessment by methods and systems expected to be used in TAEUS products. The patent supports ENDRA's proprietary approach to assessing fat content in tissue and supports the company's commercialization of a clinical application for non-invasive assessment of liver fat.

  • Should You Worry About ENDRA Life Sciences Inc’s (NASDAQ:NDRA) CEO Pay Check?
    Simply Wall St.8 months ago

    Should You Worry About ENDRA Life Sciences Inc’s (NASDAQ:NDRA) CEO Pay Check?

    Francois Michelon took the helm as ENDRA Life Sciences Inc’s (NASDAQ:NDRA) CEO and grew market cap to US$7.37M recently. Understanding how CEOs are incentivised to run and grow their companyRead More...